Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...
March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage trial, putting the company on ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex executives warned that Casgevy, its ...
Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...
Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...
- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results